Mereo BioPharma Group PLC (MREO)
3.68
+0.10
(+2.79%)
USD |
NASDAQ |
Nov 21, 16:00
3.675
0.00 (0.00%)
After-Hours: 20:00
Mereo BioPharma Group Net Income (Quarterly): -15.00M for Sept. 30, 2024
Net Income (Quarterly) Chart
Historical Net Income (Quarterly) Data
| Date | Value |
|---|---|
| September 30, 2024 | -15.00M |
| June 30, 2024 | -12.26M |
| March 31, 2024 | -8.951M |
| December 31, 2023 | -9.109M |
| Date | Value |
|---|---|
| September 30, 2023 | -6.531M |
| June 30, 2023 | -1.751M |
| March 31, 2023 | -12.08M |
Net Income Definition
Net Income is the total amount of profit earned by a company. This metric boils down to the overall profit that is left from the revenue that a company receives after taking out various operational line items like cost of goods sold, income tax expense, SG&A expense, etc. Eventually, all companies would want to have a consistent positive and growing net income, so that this can be used for various purposes like reinvesting into the company, paying off debt, and potentially paying out dividends to shareholders.
Net Income (Quarterly) Range, Past 5 Years
-15.00M
Minimum
Sep 2024
-1.751M
Maximum
Jun 2023
-9.382M
Average
-9.109M
Median
Dec 2023
Net Income (Quarterly) Benchmarks
| NuCana PLC | -8.826M |
| TC BioPharm (Holdings) PLC | -4.213M |
| Biodexa Pharmaceuticals PLC | -- |
| Adaptimmune Therapeutics PLC | -17.62M |
| Bicycle Therapeutics PLC | -50.80M |
Net Income (Quarterly) Related Metrics
| Total Expenses (Quarterly) | 9.147M |
| EPS Diluted (Quarterly) | -0.10 |
| Enterprise Value | 495.96M |
| Earnings Yield | -8.15% |